Primecap Management Co. CA Raises Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Primecap Management Co. CA grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQVFree Report) by 0.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 325,176 shares of the medical research company’s stock after buying an additional 1,220 shares during the period. Primecap Management Co. CA owned 0.18% of IQVIA worth $68,755,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Rise Advisors LLC bought a new position in shares of IQVIA in the first quarter worth approximately $31,000. Versant Capital Management Inc boosted its holdings in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after buying an additional 110 shares during the period. Riverview Trust Co purchased a new stake in IQVIA in the 1st quarter worth $32,000. Opal Wealth Advisors LLC bought a new stake in IQVIA during the second quarter valued at about $27,000. Finally, International Assets Investment Management LLC bought a new position in shares of IQVIA in the second quarter worth about $32,000. 89.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on IQV. Robert W. Baird boosted their price target on IQVIA from $235.00 to $251.00 and gave the stock a “neutral” rating in a report on Tuesday, July 23rd. JPMorgan Chase & Co. boosted their target price on shares of IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a report on Monday, August 5th. Truist Financial raised their target price on shares of IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Evercore ISI increased their price objective on shares of IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Finally, Argus raised IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $266.67.

Check Out Our Latest Analysis on IQV

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.60% of the company’s stock.

IQVIA Price Performance

IQV stock opened at $239.98 on Wednesday. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The stock has a market cap of $43.75 billion, a PE ratio of 32.78, a P/E/G ratio of 2.24 and a beta of 1.49. The company has a 50-day moving average price of $239.12 and a 200 day moving average price of $234.12.

IQVIA (NYSE:IQVGet Free Report) last released its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. During the same quarter in the prior year, the firm posted $2.22 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

IQVIA Profile

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Stories

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVFree Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.